博济医药(300404) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 66,938,495.11, a 37.21% increase year-on-year[7] - Net profit attributable to shareholders surged by 185.62% to CNY 7,592,319.58 for the quarter[7] - Basic earnings per share rose by 184.75% to CNY 0.0336[7] - Operating profit surged by 268.67% to ¥28,229,425.03 driven by increased revenue and improved gross margin[19] - Net profit increased by 255.56% to ¥24,437,211.89 reflecting higher operating income and gross margin[21] - The total comprehensive income rose by 219.20% to ¥23,587,317.77, mainly due to the increase in net profit[21] - The total profit for the quarter was CNY 11,397,889.14, significantly higher than CNY 4,326,227.29 in the same quarter last year[48] - The net profit for the third quarter reached CNY 9,571,092.22, compared to CNY 3,600,393.69 in the same period last year, representing a growth of approximately 166%[48] - The total profit for the third quarter was CNY 28,618,514.38, compared to CNY 7,763,309.57 in the same quarter last year, marking an increase of about 268.5%[55] Cash Flow - The net cash flow from operating activities increased significantly by 222.74% to CNY 9,674,573.09[7] - Cash flow from operating activities improved significantly to ¥53,901,225.56, a 6669.72% increase compared to the previous year[23] - The net cash flow from operating activities for Q3 2020 was ¥53,901,225.56, a significant improvement compared to a negative cash flow of ¥820,449.64 in Q3 2019, indicating a recovery in operational performance[63] - Total cash inflow from operating activities reached ¥219,856,846.37, up from ¥153,662,527.64 in the same period last year, reflecting a year-over-year increase of approximately 43%[63] - The company reported a net cash outflow from investing activities of ¥34,854,414.43, a decline from a positive cash flow of ¥11,387,224.40 in Q3 2019, highlighting increased investment expenditures[64] - Cash inflow from financing activities was ¥50,966,715.62, compared to ¥15,018,500.00 in Q3 2019, representing a substantial increase of over 238%[64] Assets and Liabilities - Total assets increased by 12.30% to CNY 710,955,847.92 compared to the end of the previous year[7] - The total liabilities increased to CNY 220,852,733.37 from CNY 177,003,294.01, showing a growth in financial obligations[40] - The company's equity attributable to shareholders increased to CNY 452,007,712.55 from CNY 422,651,741.36, reflecting improved financial health[40] - Total assets amounted to CNY 633,081,946.60, with current assets at CNY 286,432,776.45 and non-current assets at CNY 346,649,170.15[70] - Total liabilities reached CNY 177,003,294.01, with current liabilities at CNY 160,914,970.92 and non-current liabilities at CNY 16,088,323.09[72] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,138[10] - The top shareholder, Wang Tingchun, holds 35.57% of the shares, amounting to 80,618,642 shares[10] - The company did not engage in any repurchase transactions during the reporting period[11] Research and Development - Research and development expenses rose by 43.36% to ¥16,784,207.58 as the company increased its investment in R&D[19] - Research and development expenses for the quarter were CNY 4,348,126.55, an increase from CNY 3,399,334.52 in the previous period[50] - Research and development expenses for the third quarter amounted to CNY 11,599,267.55, up from CNY 6,844,286.18, reflecting a year-over-year increase of approximately 69.5%[58] Capital and Financing - The company plans to raise up to ¥343.20 million through a non-public offering of A-shares, with a maximum of 67,603,380 shares to be issued[24] - The company reduced its short-term borrowings by 113.27% to ¥31,990,000.00 due to increased bank loans during the period[17] - The company completed the change of its registered capital from ¥174,322,655 to ¥226,619,451 following the capital increase[27] Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[32] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[33] - The report indicates that the third-quarter financials were not audited, which may affect the reliability of the data presented[78] Future Outlook - Future outlook and performance guidance were not explicitly detailed in the report[79] - The company has not reported any new product developments or market expansions in this quarter[79] - There are no indications of mergers or acquisitions in the current financial report[79]